The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs

Maggi, Paolo; Montinaro, Vincenzo; Rusconi, Stefano; Biagio, Antonio Di; Bellagamba, Rita; Bonfanti, Paolo; Calza, Leonardo; Corsi, Paola; Montella, Francesco; Mussini, Cristina

doi:10.1310/hct1503-87

Cited by 13 publications

(9 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, changes in eGFR do not necessarily reflect changes in true GFR, as calculated by iohexol clearance. 18 , 19 In our sample, this reduction was slight but statistically significant, both in patients starting first-line therapy with a RPV-based regimen and in cART-experienced ones in line with previous reports of clinical trials. 8 …”

Section: Discussionsupporting

confidence: 90%

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

Bagella¹,

Socio²,

Ricci³

et al. 2018

IDR

Self Cite

View full text Add to dashboard Cite

Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce.MethodsWe investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study.ResultsWe enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5 years, mean CD4 600 ± 327 cell/μL, mean HIV-RNA 3.80 ± 1.15 log10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p=0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 (p=0.0008) and 72 (p=0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 (p=0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation.ConclusionIn conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored.

show abstract

Section: Discussionsupporting

confidence: 90%

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

Bagella¹,

Socio²,

Ricci³

et al. 2018

IDR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Inhibition of creatinine secretion by the proximal renal tubule with such transporter inhibitors (rilpivirine, cobicistat, dolutegravir, etc) will require further efforts in estimating the renal GFR. Changes in calculated GFR do not reflect changes in true GFR, as calculated by iohexol clearance [ 30 , 31 ]. Finally, we reported 2 cases of renal-related discontinuation, both being tubular dysfunctions and both with a history of TDF use.…”

Section: Discussionmentioning

confidence: 99%

Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014

Cazanave

Reigadas

Mazubert

et al. 2015

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…13 14 DTG has also been related to neural-tube defects in newborns of mothers in treatment with this drug. 15 Moreover, concerns have been raised about weight gain 16 and a decline in renal function in patients taking DTG, 17 the latter a problem that could be related to the effect of DTG on organic cation transporter 2 (OCT2). 18 To further investigate DTG tolerability and to assess the efficacy of DTG-based in clinical practice, several Italian clinicians joined their efforts creating a large observational cohort analysing patients starting DTG in real-life scenario.…”

Section: Introductionmentioning

confidence: 99%

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)

et al. 2019

Self Cite

View full text Add to dashboard Cite

PurposeThe Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) cohort was established in Italy in 2016 to evaluate the overall efficacy and tolerability of dolutegravir (DTG)-based antiretroviral (ARV) regimens in clinical practice.ParticipantsThe ODOACRE cohort enrols all adult HIV-1-infected patients, both treatment-naïve and treatment-experienced, starting a DTG-based ARV regimen, in 11 clinical centres in Italy from 2014.Findings to dateIn recent years, various works by the ODOACRE cohort have been produced, demonstrating the high efficacy and tolerability of DTG-based ARV regimens in clinical practice, both in ART-naïve (in the setting of acute HIV-1 infection and late presenters patient) and experienced patients. We confirmed the virological efficacy of DTG-based regimens and we evaluated predictors of virological failure. We investigated cause of discontinuation and evaluated tolerability and metabolic profile of the regimens. Within these investigations, we explored particularly the use of DTG in simplification in two-drug regimen with either rilpivirine or lamivudine. We also compared DTG-based regimens with other integrase inhibitors in clinical practice.Future plansTo continue to study long-term efficacy and tolerability of DTG-based regimens is the purpose of the ODOACRE cohort.

show abstract

The Problem of Renal Function Monitoring in Patients Treated With the Novel Antiretroviral Drugs

Cited by 13 publications

References 31 publications

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project

Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012–2014

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)

Contact Info

Product

Resources

About